Please use this identifier to cite or link to this item:
|Title:||Incretin-based therapies: New treatments for type 2 diabetes in the new millennium|
|Citation:||Therapeutics and Clinical Risk Management, 2009; 5(1):683-698|
|Publisher:||Dove Medical Press Ltd.|
|Joan Khoo, Christopher K Rayner, Karen L Jones, and Michael Horowitz|
|Abstract:||The advent of ‘incretin-based therapies’ – GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors – which result in improvements in glycemic control comparable to those with existing oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic β-cell function, represents a major therapeutic advance in the management of type 2 diabetes. Gastrointestinal adverse effects occur commonly with GLP-1 agonists, and rarely with DPP-4 inhibitors, but are dose-dependent and usually transient. The low risk of hypoglycemia, and beneficial or neutral effects on body weight, render GLP-1 agonists and DPP-4 inhibitors suitable alternatives to insulin secretagogues and insulin in overweight and elderly patients. Incretin-based therapies also improve quality of life in patients with type 2 diabetes, and may be cost-effective in the long term.|
|Keywords:||incretin; type 2 diabetes; therapy; GLP‑1 DPP‑4|
|Rights:||© 2009 Khoo et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.